Insider Transactions in Q2 2024 at Natera, Inc. (NTRA)
Insider Transaction List (Q2 2024)
Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
May 30
2024
|
Gail Boxer Marcus |
SELL
Open market or private sale
|
Direct |
2,000
-9.69%
|
$220,000
$110.17 P/Share
|
May 28
2024
|
Rowan E Chapman |
SELL
Open market or private sale
|
Direct |
4,856
-49.24%
|
$529,304
$109.09 P/Share
|
May 28
2024
|
John Fesko PRESIDENT, CHIEF BUS. OFFICER |
SELL
Open market or private sale
|
Direct |
1,438
-1.29%
|
$156,742
$109.96 P/Share
|
May 28
2024
|
Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS |
SELL
Open market or private sale
|
Direct |
1,647
-1.42%
|
$179,523
$109.96 P/Share
|
May 23
2024
|
Jonathan Sheena |
SELL
Open market or private sale
|
Indirect |
1,000
-0.36%
|
$108,000
$108.44 P/Share
|
May 16
2024
|
Jonathan Sheena |
SELL
Bona fide gift
|
Direct |
11,853
-3.72%
|
-
|
May 15
2024
|
Steven Leonard Chapman CEO AND PRESIDENT |
SELL
Open market or private sale
|
Direct |
6,779
-1.51%
|
$725,353
$107.09 P/Share
|
May 10
2024
|
Jonathan Sheena |
SELL
Open market or private sale
|
Direct |
2,700
-0.17%
|
$283,500
$105.39 P/Share
|
May 10
2024
|
Daniel Rabinowitz SEC. AND CHIEF LEGAL OFFICER |
SELL
Open market or private sale
|
Direct |
30,000
-3.36%
|
$3,120,000
$104.15 P/Share
|
May 10
2024
|
Daniel Rabinowitz SEC. AND CHIEF LEGAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+11.34%
|
$570,000
$19.68 P/Share
|
May 08
2024
|
Matthew Rabinowitz EXECUTIVE CHAIRMAN |
BUY
Exercise of conversion of derivative security
|
Direct |
215,000
+14.28%
|
$1,075,000
$5.4 P/Share
|
May 01
2024
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,866
-0.68%
|
$175,404
$94.2 P/Share
|
Apr 29
2024
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,238
-1.75%
|
$115,134
$93.14 P/Share
|
Apr 29
2024
|
Steven Leonard Chapman CEO AND PRESIDENT |
SELL
Open market or private sale
|
Direct |
4,084
-1.77%
|
$379,812
$93.14 P/Share
|
Apr 29
2024
|
Daniel Rabinowitz SEC. AND CHIEF LEGAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,057
-0.51%
|
$98,301
$93.14 P/Share
|
Apr 29
2024
|
Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS |
SELL
Open market or private sale
|
Direct |
1,196
-1.02%
|
$111,228
$93.14 P/Share
|
Apr 29
2024
|
John Fesko PRESIDENT, CHIEF BUS. OFFICER |
SELL
Open market or private sale
|
Direct |
929
-0.83%
|
$86,397
$93.14 P/Share
|
Apr 26
2024
|
Roelof Botha |
BUY
Grant, award, or other acquisition
|
Direct |
766
+1.8%
|
-
|
Apr 26
2024
|
Herm Rosenman |
BUY
Grant, award, or other acquisition
|
Direct |
732
+0.58%
|
-
|
Apr 26
2024
|
Rowan E Chapman |
BUY
Grant, award, or other acquisition
|
Direct |
488
+4.72%
|
-
|
Apr 26
2024
|
Gail Boxer Marcus |
BUY
Grant, award, or other acquisition
|
Direct |
488
+2.31%
|
-
|
Apr 26
2024
|
Roy D. Baynes |
BUY
Grant, award, or other acquisition
|
Direct |
169
+1.33%
|
-
|
Apr 26
2024
|
James Healy |
BUY
Grant, award, or other acquisition
|
Direct |
210
+0.49%
|
-
|
Apr 26
2024
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
751
-1.05%
|
$69,092
$92.0 P/Share
|
Apr 25
2024
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
705
-0.98%
|
$62,745
$89.55 P/Share
|
Apr 25
2024
|
Jonathan Sheena |
SELL
Open market or private sale
|
Indirect |
1,000
-0.72%
|
$89,000
$89.55 P/Share
|
Apr 24
2024
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
937
-1.28%
|
$87,141
$93.0 P/Share
|
Apr 23
2024
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,523
-2.04%
|
$138,593
$91.38 P/Share
|
Apr 23
2024
|
Steven Leonard Chapman CEO AND PRESIDENT |
SELL
Open market or private sale
|
Direct |
2,552
-1.1%
|
$232,232
$91.38 P/Share
|
Apr 23
2024
|
John Fesko PRESIDENT, CHIEF BUS. OFFICER |
SELL
Open market or private sale
|
Direct |
522
-0.47%
|
$47,502
$91.38 P/Share
|
Apr 23
2024
|
Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS |
SELL
Open market or private sale
|
Direct |
531
-0.45%
|
$48,321
$91.38 P/Share
|
Apr 23
2024
|
Daniel Rabinowitz SEC. AND CHIEF LEGAL OFFICER |
SELL
Open market or private sale
|
Direct |
787
-0.38%
|
$71,617
$91.38 P/Share
|
Apr 22
2024
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250
+1.65%
|
-
|
Apr 21
2024
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,145
+1.54%
|
-
|
Apr 21
2024
|
Steven Leonard Chapman CEO AND PRESIDENT |
BUY
Exercise of conversion of derivative security
|
Direct |
1,775
+0.76%
|
-
|
Apr 21
2024
|
Daniel Rabinowitz SEC. AND CHIEF LEGAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
644
+0.31%
|
-
|
Apr 21
2024
|
Jonathan Sheena |
BUY
Exercise of conversion of derivative security
|
Direct |
143
+0.04%
|
-
|
Apr 20
2024
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,521
+2.06%
|
-
|
Apr 20
2024
|
Steven Leonard Chapman CEO AND PRESIDENT |
BUY
Exercise of conversion of derivative security
|
Direct |
3,386
+1.44%
|
-
|
Apr 20
2024
|
Daniel Rabinowitz SEC. AND CHIEF LEGAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
856
+0.41%
|
-
|
Apr 20
2024
|
Jonathan Sheena |
BUY
Exercise of conversion of derivative security
|
Direct |
190
+0.06%
|
-
|
Apr 16
2024
|
Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS |
SELL
Open market or private sale
|
Direct |
80,000
-22.35%
|
$7,200,000
$90.7 P/Share
|
Apr 15
2024
|
Steven Leonard Chapman CEO AND PRESIDENT |
SELL
Open market or private sale
|
Direct |
6,816
-0.98%
|
$633,888
$93.67 P/Share
|
Apr 03
2024
|
Jonathan Sheena |
SELL
Open market or private sale
|
Direct |
26,700
-2.63%
|
$2,456,400
$92.49 P/Share
|
Apr 02
2024
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,378
-1.91%
|
$126,776
$92.62 P/Share
|